GlaxoSmithKline PLC
LSE:GSK

Watchlist Manager
GlaxoSmithKline PLC Logo
GlaxoSmithKline PLC
LSE:GSK
Watchlist
Price: 1 342 GBX 2.48% Market Closed
Market Cap: 54.7B GBX
Have any thoughts about
GlaxoSmithKline PLC?
Write Note

Intrinsic Value

The intrinsic value of one GSK stock under the Base Case scenario is 2 400.47 GBX. Compared to the current market price of 1 342 GBX, GlaxoSmithKline PLC is Undervalued by 44%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

GSK Intrinsic Value
2 400.47 GBX
Undervaluation 44%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
GlaxoSmithKline PLC

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for GSK cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about GSK?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about GlaxoSmithKline PLC

Provide an overview of the primary business activities
of GlaxoSmithKline PLC.

What unique competitive advantages
does GlaxoSmithKline PLC hold over its rivals?

What risks and challenges
does GlaxoSmithKline PLC face in the near future?

Summarize the latest earnings call
of GlaxoSmithKline PLC.

What significant events have occurred
in GlaxoSmithKline PLC over the past months?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for GlaxoSmithKline PLC.

Provide P/S
for GlaxoSmithKline PLC.

Provide P/E
for GlaxoSmithKline PLC.

Provide P/OCF
for GlaxoSmithKline PLC.

Provide P/FCFE
for GlaxoSmithKline PLC.

Provide P/B
for GlaxoSmithKline PLC.

Provide EV/S
for GlaxoSmithKline PLC.

Provide EV/GP
for GlaxoSmithKline PLC.

Provide EV/EBITDA
for GlaxoSmithKline PLC.

Provide EV/EBIT
for GlaxoSmithKline PLC.

Provide EV/OCF
for GlaxoSmithKline PLC.

Provide EV/FCFF
for GlaxoSmithKline PLC.

Provide EV/IC
for GlaxoSmithKline PLC.

Show me price targets
for GlaxoSmithKline PLC made by professional analysts.

What are the Revenue projections
for GlaxoSmithKline PLC?

How accurate were the past Revenue estimates
for GlaxoSmithKline PLC?

What are the Net Income projections
for GlaxoSmithKline PLC?

How accurate were the past Net Income estimates
for GlaxoSmithKline PLC?

What are the EPS projections
for GlaxoSmithKline PLC?

How accurate were the past EPS estimates
for GlaxoSmithKline PLC?

What are the EBIT projections
for GlaxoSmithKline PLC?

How accurate were the past EBIT estimates
for GlaxoSmithKline PLC?

Compare the revenue forecasts
for GlaxoSmithKline PLC with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of GlaxoSmithKline PLC and its key competitors using the latest financial data.

Compare historical revenue growth rates
of GlaxoSmithKline PLC against its competitors.

Analyze the profit margins
(gross, operating, and net) of GlaxoSmithKline PLC compared to its peers.

Compare the P/E ratios
of GlaxoSmithKline PLC against its peers.

Discuss the investment returns and shareholder value creation
comparing GlaxoSmithKline PLC with its peers.

Analyze the financial leverage
of GlaxoSmithKline PLC compared to its main competitors.

Show all profitability ratios
for GlaxoSmithKline PLC.

Provide ROE
for GlaxoSmithKline PLC.

Provide ROA
for GlaxoSmithKline PLC.

Provide ROIC
for GlaxoSmithKline PLC.

Provide ROCE
for GlaxoSmithKline PLC.

Provide Gross Margin
for GlaxoSmithKline PLC.

Provide Operating Margin
for GlaxoSmithKline PLC.

Provide Net Margin
for GlaxoSmithKline PLC.

Provide FCF Margin
for GlaxoSmithKline PLC.

Show all solvency ratios
for GlaxoSmithKline PLC.

Provide D/E Ratio
for GlaxoSmithKline PLC.

Provide D/A Ratio
for GlaxoSmithKline PLC.

Provide Interest Coverage Ratio
for GlaxoSmithKline PLC.

Provide Altman Z-Score Ratio
for GlaxoSmithKline PLC.

Provide Quick Ratio
for GlaxoSmithKline PLC.

Provide Current Ratio
for GlaxoSmithKline PLC.

Provide Cash Ratio
for GlaxoSmithKline PLC.

What is the historical Revenue growth
over the last 5 years for GlaxoSmithKline PLC?

What is the historical Net Income growth
over the last 5 years for GlaxoSmithKline PLC?

What is the current Free Cash Flow
of GlaxoSmithKline PLC?

Discuss the annual earnings per share (EPS)
trend over the past five years for GlaxoSmithKline PLC.

Business Breakdown

GlaxoSmithKline PLC (GSK) is a global healthcare giant rooted in extensive research and development, dedicated to improving the health and well-being of people around the world. Founded in 2000 through a merger of Glaxo Wellcome and SmithKline Beecham, GSK has built a diverse portfolio that spans pharmaceuticals, vaccines, and consumer healthcare. With a strong emphasis on innovation, GSK invests heavily in R&D, focusing on tackling significant health challenges such as infectious diseases, oncology, and respiratory ailments. The company’s robust pipeline showcases its commitment to advancing medical science, promising both potential breakthroughs for patients and lucrative prospects for inv...

Read More
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
GlaxoSmithKline PLC

Current Assets 16.8B
Cash & Short-Term Investments 3B
Receivables 7.8B
Other Current Assets 6B
Non-Current Assets 41.3B
Long-Term Investments 1.2B
PP&E 9.8B
Intangibles 22.4B
Other Non-Current Assets 7.9B
Current Liabilities 20.3B
Accounts Payable 14.2B
Other Current Liabilities 6.1B
Non-Current Liabilities 23.3B
Long-Term Debt 13.6B
Other Non-Current Liabilities 9.8B
Efficiency

Earnings Waterfall
GlaxoSmithKline PLC

Revenue
31.4B GBP
Cost of Revenue
-8.5B GBP
Gross Profit
22.9B GBP
Operating Expenses
-15.3B GBP
Operating Income
7.6B GBP
Other Expenses
-3.6B GBP
Net Income
4B GBP

Free Cash Flow Analysis
GlaxoSmithKline PLC

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

GSK's recent earnings call highlighted a solid performance, with Q3 sales growing 2% to GBP 8 billion and year-to-date growth at 9%. The Specialty Medicines segment drove growth, soaring 19%. Core operating profit and EPS increased 5%, despite a significant charge from Zantac litigation. For 2024, GSK maintains a sales growth guidance of 7% to 9% and profit growth of 11% to 13%. While vaccine sales sagged 15% amid shifting market conditions, robust prospects in oncology and respiratory treatments buoyed optimism. Consequently, cash from operations improved to GBP 5.3 billion, supporting future investments and an increased dividend, reinforcing GSK's focus on sustainable growth and shareholder returns.

What is Earnings Call?
Fundamental Scores

GSK Profitability Score
Profitability Due Diligence

GlaxoSmithKline PLC's profitability score is 71/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Positive Gross Profit
Positive Free Cash Flow
Positive Net Income
71/100
Profitability
Score

GlaxoSmithKline PLC's profitability score is 71/100. The higher the profitability score, the more profitable the company is.

GSK Solvency Score
Solvency Due Diligence

GlaxoSmithKline PLC's solvency score is 45/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
Long-Term Solvency
Low D/E
Short-Term Solvency
45/100
Solvency
Score

GlaxoSmithKline PLC's solvency score is 45/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

GSK Price Targets Summary
GlaxoSmithKline PLC

Wall Street analysts forecast GSK stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GSK is 1 743.66 GBX with a low forecast of 1 363.5 GBX and a high forecast of 2 740.5 GBX.

Lowest
Price Target
1 363.5 GBX
2% Upside
Average
Price Target
1 743.66 GBX
30% Upside
Highest
Price Target
2 740.5 GBX
104% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for GSK?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for GSK is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

GSK News

Other Videos

Profile

GlaxoSmithKline PLC Logo
GlaxoSmithKline PLC

Country

United Kingdom

Industry

Pharmaceuticals

Market Cap

54.7B GBP

Dividend Yield

4.55%

Description

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. The company is headquartered in Brentford, Middlesex and currently employs 90,096 full-time employees. The firm researches and develops a range of products in three primary areas: Pharmaceuticals, Vaccines and Consumer Healthcare. Its product formulations include tablets, creams/ointments, inhalers, injections, liquids and sterile products. Its Pharmaceuticals business has a portfolio of established medicines in respiratory, human immunodeficiency virus (HIV), immuno-inflammation and oncology. Its Vaccines business has a portfolio of vaccines to help protect people from a range of diseases throughout their lives. Its vaccines tackle diseases, including pneumococcal disease, meningitis, hepatitis, rotavirus, whooping cough and influenza. Its Consumer Healthcare business combines science and consumer insights to create everyday healthcare brands that consumers trust, and experts recommend for oral health, pain relief, cold, flu and allergy, digestive health and vitamins, minerals and supplements.

Contact

MIDDLESEX
Brentford
G S K House, 980 Great West Road
www.gsk.com

IPO

1972-05-22

Employees

90 096

Officers

CEO & Director
Ms. Emma Natasha Walmsley
CFO & Executive Director
Ms. Julie Belita Brown
Chief Digital & Technology Officer
Ms. Shobie Ramakrishnan
Chief Scientific Officer and Head of R&D
Mr. Tony Wood
Head of Investor Relations
Ms. Sarah Elton-Farr
Senior VP & Group General Counsel of Legal & Compliance
Mr. James Ford
Show More
Senior Vice President of Global Communications & CEO Office
Ms. Sally Jackson
President of Corporate Development
Mr. David Simon Redfern BSc (Hons), CA
Chief People Officer
Ms. Diana Conrad
President of Global Affairs
Mr. Philip C. Thomson
Show Less

See Also

Discover More
What is the Intrinsic Value of one GSK stock?

The intrinsic value of one GSK stock under the Base Case scenario is 2 400.47 GBX.

Is GSK stock undervalued or overvalued?

Compared to the current market price of 1 342 GBX, GlaxoSmithKline PLC is Undervalued by 44%.

Back to Top